Table II.
Incidence of ACH induced by MNU.
| Days after MNU treatment
|
||||||
|---|---|---|---|---|---|---|
| Treatment | Diet | 7 | 14 | 21 | 28 | 60 |
| Vehicle | Basalb | 0 (0/6)d | 0 (0/6) | 0 (0/5) | 0 (0/5) | 0 (0/10) |
| AAc | 0 (0/6) | 0 (0/6) | 0 (0/5) | 0 (0/5) | 0 (0/5) | |
| MNUa | Basal | 0 (0/6) | 0 (0/6) | 0 (0/5) | 0 (0/5) | 100 (5/5) |
| AA | 0 (0/6) | 0 (0/6) | 0 (0/5) | 20 (1/5)e | 75 (6/8)e | |
a
35 mg/kg MNU was injected intraperitoneally at birth (day 0);
b
Basal diet contained 0.008% arachidonic acid (AA);
c
AA diet contained 2.0% arachidonic acid (AA);
d
Percentage of incidence (number of animals with hyperplasia/total number of animals examined) was indicated;
e
Without significant difference between basal diet- and AA-rich diet-fed rats in MNU-treated groups. ACH, acinar cell hyperplasia; MNU, N-methyl-N-nitrosourea.